Opus Genetics Stock
Opus Genetics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- George Magrath
- Employees
- 28
- Market cap
- $319 M
- IPO
- 19/01/2015
- Web
- opusgtx.com
US biopharmaceutical company Opus Genetics, Inc., trading under the ticker symbol IRD, operates in the healthcare/biotechnology sector and focuses on developing innovative therapies in ophthalmology. The company aims to address unmet medical needs for patients with refractive or retinal eye diseases. A central…
AI-generated company profile based on the figures on this page, last updated on 01/10/2026. Not investment advice.
Opus Genetics stock: price history
1D
-5.2%
1W
-17.4%
1M
-29.0%
6M
-33.2%
YTD
+91.0%
1Y
+91.0%
2Y
+200.0%
5Y
–
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~28% weaker price swings than usual
Opus Genetics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Business model with weaknesses or early megatrend headwind.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for ophthalmological diseases. The company addresses unmet medical needs in patients with refractive and retinal disorders. Its portfolio includes phentolamine for the treatment of mydriasis as well as compounds such as APX3330, which has been tested in Phase II for diabetic retinopathy. Additional goals include the development of products to treat presbyopia and low-light vision problems through Phase III clinical trials.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Moderate
- Moat
- None
- Moat type
- None
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Opus Genetics
Analyst assessment of Opus Genetics
PRICE TARGET LOW
US$8.00
CONSENSUS
US$12.60
MEDIAN
US$10.00
PRICE TARGET HIGH
US$20.00
0
STRONG BUY
9
BUY
0
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 16/10/2026
Opus Genetics stock metrics
P/E
-3.02
P/B
-28.23
EV/EBITDA
-2.53
RETURN ON EQUITY
62.4%
NET MARGIN
-1,072.6%
DEBT/EQUITY
-2.69
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
42.4%
FLOAT SHARES
35,245,805
AVG. DAILY VOLUME (30D)
4,039,502
Insider transactions (SEC)
Foundation Fighting Blindness Retinal Degeneration Fund
Magrath George
Magrath George
Gallagher Cam
Gagnon Robert E.
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -5.2%
Search (Google Trends)
Forums (Reddit)
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Opus Genetics stock
What does Opus Genetics do?
Opus Genetics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is George Magrath, the company employs around 28 people.
The IPO was on 19/01/2015; the stock trades on NASDAQ under the ticker IRD.
What do analysts say about Opus Genetics stock?
9 analysts rate the stock, the consensus is Buy (as of 16/10/2026).
The average price target is US$12.60, ranging from US$8.00 to US$20.00, with a median of US$10.00.
This is an external assessment, not a statement by Market Jury.
When does Opus Genetics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -28% stronger than usual.
Does Opus Genetics pay a dividend?
No, Opus Genetics currently does not pay a dividend.
Which stocks are comparable to Opus Genetics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Opus Genetics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Opus Genetics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.